FY2028 EPS Estimates for CapsoVision Lowered by Roth Capital

Key Points

• Roth Capital has revised its earnings estimates for CapsoVision, lowering the FY2028 EPS forecast from $0.35 to $0.33, while maintaining a "Strong-Buy" rating and a target price of $6.00.
• In their latest earnings report, CapsoVision reported an EPS of ($2.02), significantly missing analyst expectations of ($0.11).
• Other analysts have varied opinions on CapsoVision, with Wall Street Zen upgrading it to a "hold" rating and Benchmark initiating coverage with a "speculative buy" rating and a $5.00 price target.

CapsoVision, Inc. (NASDAQ:CV - Free Report) - Analysts at Roth Capital dropped their FY2028 earnings per share (EPS) estimates for shares of CapsoVision in a research note issued to investors on Thursday, August 14th. Roth Capital analyst J. Wittes now expects that the company will earn $0.33 per share for the year, down from their previous forecast of $0.35. Roth Capital has a "Strong-Buy" rating and a $6.00 price objective on the stock. Roth Capital also issued estimates for CapsoVision's FY2029 earnings at $0.54 EPS.

CapsoVision (NASDAQ:CV - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($2.02) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($1.91). The business had revenue of $3.32 million during the quarter, compared to analyst estimates of $3.20 million.

Other research analysts have also issued reports about the stock. Benchmark assumed coverage on shares of CapsoVision in a report on Monday, July 28th. They issued a "speculative buy" rating and a $5.00 target price for the company. Wall Street Zen raised shares of CapsoVision to a "hold" rating in a report on Sunday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the stock. According to MarketBeat.com, CapsoVision presently has an average rating of "Strong Buy" and a consensus target price of $5.50.

CapsoVision Price Performance

Shares of CV stock traded up $0.02 on Monday, reaching $4.00. The company's stock had a trading volume of 18,540 shares, compared to its average volume of 47,501. CapsoVision has a 1 year low of $3.49 and a 1 year high of $5.72.

CapsoVision Company Profile

We are a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal (“GI”) tract for diagnostic and screening purposes. We developed our first capsule endoscope system, currently comprising the CapsoCam Plus single-usecapsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn's disease.